Apogee Therapeutics (APGE) Competitors $37.14 -1.74 (-4.48%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$37.72 +0.58 (+1.56%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVLShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Its Competitors BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Apogee Therapeutics (NASDAQ:APGE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Which has better earnings and valuation, APGE or BBIO? Apogee Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$3.60-10.32BridgeBio Pharma$221.90M40.19-$535.76M-$3.53-13.31 Does the media prefer APGE or BBIO? In the previous week, BridgeBio Pharma had 18 more articles in the media than Apogee Therapeutics. MarketBeat recorded 22 mentions for BridgeBio Pharma and 4 mentions for Apogee Therapeutics. BridgeBio Pharma's average media sentiment score of 0.82 beat Apogee Therapeutics' score of 0.49 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer APGE or BBIO? Apogee Therapeutics presently has a consensus target price of $99.00, indicating a potential upside of 166.56%. BridgeBio Pharma has a consensus target price of $61.20, indicating a potential upside of 30.30%. Given Apogee Therapeutics' higher possible upside, equities research analysts clearly believe Apogee Therapeutics is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is APGE or BBIO more profitable? Apogee Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -28.35% -26.98% BridgeBio Pharma -524.25%N/A -94.43% Which has more volatility and risk, APGE or BBIO? Apogee Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Do institutionals and insiders believe in APGE or BBIO? 79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryApogee Therapeutics and BridgeBio Pharma tied by winning 7 of the 14 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-10.3220.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book2.337.568.145.54Net Income-$182.15M-$55.11M$3.24B$257.73M7 Day Performance0.32%3.81%0.18%-0.08%1 Month Performance-12.84%11.60%5.96%8.09%1 Year Performance-25.84%-2.11%26.24%13.02% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics3.0688 of 5 stars$37.14-4.5%$99.00+166.6%-24.8%$1.71BN/A-10.3291BBIOBridgeBio Pharma4.6361 of 5 stars$43.50-1.1%$58.85+35.3%+68.7%$8.35B$221.90M-12.32400Analyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.0895 of 5 stars$128.40+0.0%$128.06-0.3%+8.2%$8.29B$508.82M-51.98640Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2674 of 5 stars$91.20-0.4%$107.36+17.7%+387.3%$7.79B$42.28M-45.6030Analyst ForecastROIVRoivant Sciences2.8009 of 5 stars$10.74-2.3%$17.50+62.9%-1.2%$7.47B$29.05M-42.96860ELANElanco Animal Health1.4953 of 5 stars$14.48-1.1%$15.33+5.9%+9.4%$7.27B$4.44B19.579,000RVMDRevolution Medicines4.603 of 5 stars$36.67-3.2%$67.58+84.3%-17.8%$7.05B$11.58M-9.17250Analyst ForecastGap UpLEGNLegend Biotech3.3629 of 5 stars$35.87+0.6%$72.60+102.4%-26.7%$6.55B$627.24M-60.802,609GRFSGrifols3.5155 of 5 stars$8.87-2.3%$10.30+16.1%+19.7%$6.24B$7.81B7.5823,822News CoverageGap UpTGTXTG Therapeutics3.6109 of 5 stars$35.98-2.0%$40.80+13.4%+78.5%$5.83B$329M149.92290Positive NewsNUVLNuvalent3.3016 of 5 stars$77.93-3.2%$119.60+53.5%+1.8%$5.78BN/A-17.7540 Related Companies and Tools Related Companies BBIO Competitors BPMC Competitors VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors LEGN Competitors GRFS Competitors TGTX Competitors NUVL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts